Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SER-228
- Development stage
- Preclinical
- Lead developer
- Serina Therapeutics
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
SER-228 is a polymer-drug conjugate consisting of cannabidiol (CBD) covalently linked to a poly(2-oxazoline) (POZ) polymer. Developed by Serina Therapeutics using its proprietary POZ Platform™, the drug is designed to provide controlled and sustained release of CBD, potentially improving its pharmacokinetic profile and reducing dosing frequency compared to standard CBD formulations. The primary target indication for SER-228 is treatment-refractory epilepsy. In June 2020, Serina entered into an exclusive license agreement with Jazz Pharmaceuticals for the development of SER-228, but the collaboration was terminated in July 2021 following Jazz's acquisition of GW Pharmaceuticals. As of late 2023, SER-228 was positioned for IND-enabling studies.
- Other names
- POZ-cannabidiol
02
Targets
GPR55 (G protein-coupled receptor 55)TRPV1 (Transient receptor potential cation channel subfamily V member 1)ENT1 (Solute carrier family 29 member 1)
Beyond the preview
Go deeper on SER-228.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SER-228.